Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in United Kingdom
51 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1Not yet taking people in United KingdomA Study of LY4336619 in Adult Participants With Advanced Solid Tumors
- Where
- Manchester, Sutton
- Age
- 18 years and over
- People
- 370 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00 - Phase 1/2Taking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton
- Age
- 18 years and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - Phase 3Taking peopleA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Bristol, Cardiff, Cottingham, Coventry, Dundee, Glasgow, London, Manchester, Sheffield
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - Phase 1Taking peopleA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Where
- London, Manchester
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00 - Phase 2/3Taking peopleA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- Glasgow, London, Manchester, Oxford, Sutton
- Age
- 18 years and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- London, Manchester
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 2Taking peopleA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
- Where
- Bristol, Dundee, Headington, London, Norwich
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07069712 · EU 2024-516909-23-00 - Phase 1/2Taking peopleA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Where
- Cambridge, London
- Age
- 18 years and over
- People
- 560 worldwide
- Run by
- Genmab
See details and how to joinNCT03526835 · EU 2024-513627-16-01 - Phase 1Taking peopleStudy of XB010 in Subjects With Solid Tumors
- Where
- Leicester, London, Manchester
- Age
- 18 years and over
- People
- 396 worldwide
- Run by
- Exelixis
See details and how to joinNCT06545331 - Phase 1/2Taking peopleBOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
- Where
- Cardiff, Dundonald, London, Sutton
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00 - Phase 1Taking peopleA Study of MGC026 in Participants With Advanced Solid Tumors
- Where
- Oxford, Sutton
- Age
- 18 years and over
- People
- 394 worldwide
- Run by
- MacroGenics
See details and how to joinNCT06242470 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Cambridge, Coventry, London, Nottingham
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 3Taking peopleA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Where
- Belfast, Dundee, London, Manchester, Plymouth, Sutton
- Age
- 18 years and over
- People
- 510 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06644781 · EU 2023-509630-19-00 - No phaseTaking peopleBreath Research Narrow Validation for Gastrointestinal Cancer Detection
- Where
- Glasgow, Liverpool, London, Maidstone
- Age
- 18 years and over
- People
- 1,000
- Run by
- Imperial College London
See details and how to joinNCT07714538 - Phase 3Taking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Cambridge, Coventry, Dundee, London, Manchester, Sutton
- Age
- 18 years and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - Phase 3Taking peopleSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Where
- Cambridge, Dundee, Leeds, London, Manchester, Oxford
- Age
- 18 years and over
- People
- 2,130 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00 - Phase 3Taking peopleA Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Cambridge, Dundee, Metropolitan Borough of Wirral
- Age
- 18 years and over
- People
- 351 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07043400 · EU 2025-522862-58-00 - Phase 1/2Taking peopleA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Where
- Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton, Sutton
- Age
- 18 years and over
- People
- 1,438 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00 - Phase 1/2Taking peopleHTL0039732 in Participants With Advanced Solid Tumours
- Where
- Cambridge, Cardiff, Dundee, Liverpool, London, Manchester
- Age
- 18 years and over
- People
- 150
- Run by
- Cancer Research UK
See details and how to joinNCT05944237 - Phase 2WithdrawnAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Where
- Glasgow, Leeds, London, Oxford
- Age
- 18 years and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06219941 · EU 2023-508275-37-00 - Phase 1/2Taking peopleStudy of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
- Where
- Dundee, London, Metropolitan Borough of Wirral, Oxford
- Age
- 18 years and over
- People
- 392 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06005493 · EU 2023-504139-42-00 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Cambridge, Dundee, London, Manchester
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseTaking peopleEvaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery
- Where
- Guildford, London, Southampton
- Age
- 18 years and over
- People
- 164
- Run by
- Guy's and St Thomas' NHS Foundation Trust
See details and how to joinNCT07159711 - Phase 2Taking peopleStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
- Where
- Cambridge, Glasgow, Manchester
- Age
- 18 years to 64 years
- People
- 257 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00 - Phase 1Taking peopleA Phase 1/1b Study of IAM1363 in HER2 Cancers
- Where
- Chelsea, Oxford, Sutton
- Age
- 18 years and over
- People
- 383 worldwide
- Run by
- Iambic Therapeutics, Inc
See details and how to joinNCT06253871